二乙胺盐酸盐 | 14559-68-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 二乙胺盐酸盐
• 英文名称: 3-amino-pyrazinoylguanidine
• 英文别名: 3-amino-pyrazine-2-carboxylic acid carbamimidoylamide；(3-amino-pyrazine-2-carbonyl)-guanidine；3-amino-N-carbamimidoylpyrazine-2-carboxamide
• CAS: 14559-68-3
• 化学式: C₆H₈N₆O
• 分子量: 180.169
• InChiKey: GTOFYYPYNNNMLP-UHFFFAOYSA-N

物化性质

• 密度：
  1.75±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  133
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

文献信息

• Hyperuretic agents
  申请人：Beyer, Karl H., Jr.

  公开号：EP0083779A1

  公开（公告）日：1983-07-20

  Hyperuretic agents of the formula: wherein Y is 0 or NH; R is OH; NHCONR4R5; or N=C(NR4R5)2: R1 and R2 are amino, or mono- or disubstituted amino, provided that R1 and R2 may not both be amino or substituted amino; and R3 is hydrogen or halo; enhance renal excretion of urea, thereby lowering plasma urea concentration, and are therefore useful for treating hypertension, eclampsia, uremia, and similar disorders; and may be used in combination with saluretic agents such as hydrochlorothiazide for treating hypertension.

  式中 Y 是 0 或 NH；R 是 OH；NHCONR4R5；或 N=C(NR4R5)2：R1 和 R2 是氨基，或单取代或二取代氨基，但 R1 和 R2 不可都是氨基或取代氨基；R3 是氢或卤；可促进尿素的肾排泄，从而降低血浆尿素浓度，因此可用于治疗高血压、子痫、尿毒症和类似疾病；可与盐酸药（如氢氯噻嗪）联合用于治疗高血压。
• Pyrazine derivatives as medicaments for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
  申请人：Beyer, Karl H., Jr.

  公开号：EP0370987A2

  公开（公告）日：1990-05-30

  The use of at least one compound of Formula (I) for the manufacture of a medicament for controlling and/or reducing a patient's serum cholesterol and/or triglyceride level is disclosed. wherein Y is O or NH, R is OH, NHCONR⁴R⁵; or N=C(NR⁴R⁵)₂;where R⁴ and R⁵ are each independently selected from the group consisting of hydrogen; C₁₋₁₀alkyl, straight or branched chain; aryl C₁₋₄alkyl; mono- or disubstituted aryl C₁₋₄ alkyl where the substituents are fluoro, chlore, bromo, iodo, or C₁₋₁₀alkyl, straight or branched chain; R¹ and R² are each independently selected from the group consisting of hydrogen, animo, and mono- or di-substituted amino where the substituents are C₁₋₁₀alkyl, straight or branched chain, C₃₋₈ cycloalkyl; provided that R¹ and R² may not both be amino or substituted amino and; R³ is hydrogen, trifluoromethyl, fluoro; chloro, bromo, or iodo, or a pharmaceutically acceptable salt thereof.

  本发明公开了至少一种式（I）化合物用于制造控制和/或降低患者血清胆固醇和/或甘油三酯水平的药物。 其中 Y 是 O 或 NH、 R为OH、NHCONR⁴R⁵；或N=C(NR⁴R⁵)₂；其中 R⁴ 和 R⁵各自独立地选自氢、C₁₋₁₀直链或支链烷基、芳基 C₁₋₄烷基组成的组；单取代或二取代芳基 C₁₋₄烷基，其中取代基为氟、氯、溴、碘或 C₁₋₁₀烷基，直链或支链； R¹ 和 R² 各自独立地选自氢、亚氨基、单或双取代氨基（其中取代基为 C₁₋₁₀烷基、直链或支链、C₃₋₈环烷基）组成的组；但 R¹ 和 R² 不得同时为氨基或取代氨基，并且 R³ 是氢、三氟甲基、氟、氯、溴或碘，或 其药学上可接受的盐。
• Use of amiloride and other pyrazine derivatives for preventing or treating ocular neovascularization
  申请人：CELTRIX PHARMACEUTICALS, INC.

  公开号：EP0451130A2

  公开（公告）日：1991-10-09

  A method and composition for preventing and/or treating ocular (including corneal, iridial, retinal, and choroidal) neovascularization in a patient comprises administration of a compound in the class of pyrazine derivative, e.g. amiloride, or one of its derivatives or congeners or one of their pharmaceutically acceptable salts and/or solvates, to the patient. The pyrazine derivatives can be administered by topical administration to ocular tissues with a suitable carrier such as an artificial tear carrier or a petroleum-based ointment, among others. The pyrazine derivative can also be administered orally, by intravenous administration, or by an intraocular implant.

  一种用于预防和/或治疗患者眼部（包括角膜、虹膜、视网膜和脉络膜）新生血管的方法和组合物包括向患者施用吡嗪衍生物类化合物，例如阿米洛利或其衍生物或同系物之一或其药学上可接受的盐和/或溶液之一。吡嗪衍生物可以通过适当的载体，如人工泪液载体或石油基软膏等，局部给药到眼部组织。吡嗪衍生物也可以通过口服、静脉注射或眼内植入的方式给药。
• COMPOSITION AND METHOD FOR TREATING DIABETES
  申请人：Beyer, Camille F.

  公开号：EP1161242A1

  公开（公告）日：2001-12-12
• EP1161242A4
  申请人：——

  公开号：EP1161242A4

  公开（公告）日：2004-06-30